See ratings and reviews when you sign up for an account.

Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth

This study is currently Recruiting

October 2011 By Wayne State University

First Recieved on August 9, 2010

Last Updated on October 17, 2011

Sponsor: Wayne State University
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: Wayne State University
Identifier: NCT01203085


The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT) Pediatric Scale for use in evaluation in natural history CMT study.

Study Type: Observational
Study Design: Observational Model: Case-Only, Time Perspective: Prospective


Ages Eligible for Study:N/A
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: All patients MUST be seen in person at one of the participating centers for enrollment in this study. - Children (< 21 years of age) - Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4 Exclusion Criteria: - Known diagnoses of acquired neuropathy including toxic (e. g. medication related neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory [acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory demyelinating polyneuropathy (CIDP)] polyneuropathies; neuropathy related to leukodystrophy, congenital muscular dystrophy; and patients with severe general medical conditions. - Entirely normal conduction velocities of upper and lower limbs as this suggests that the subject may not have a neuropathy.


  • Investigator: Michael E Shy, MD - Principal Investigator - Wayne State University


  • Wayne State University

    Detroit, Michigan 48201 United States

  • University of Rochester

    Rochester, New York 14642 United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104 United States

  • Children's Hospital of Westmead

    Sydney, New South Wales 2145 Australia

  • National Hospital of Neurology and Neurosurgery

    London, England WC1N 3BG United Kingdom

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.